Další formáty:
BibTeX
LaTeX
RIS
@article{970398,
author = {Halámková, Jana and Kiss, Igor and Pavlovský, Zdeněk and Jarkovský, Jiří and Tomášek, Jiří and Tuček, Štěpán and Hanakova, Lada and Moulis, Mojmír and Čech, Zbyněk and Zavřelová, Jiřina and Penka, Miroslav},
article_number = {112},
doi = {http://dx.doi.org/10.5754/hge10232},
keywords = {Colorectal cancer; Plasminogen activator system; PAI 1; PAI 2; uPA; uPAR},
language = {eng},
issn = {0172-6390},
journal = {Hepatogastroenterology},
title = {Clinical Relevance of uPA, uPAR, PAI 1 and PAI 2 Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patients},
volume = {58},
year = {2011}
}
TY - JOUR
ID - 970398
AU - Halámková, Jana - Kiss, Igor - Pavlovský, Zdeněk - Jarkovský, Jiří - Tomášek, Jiří - Tuček, Štěpán - Hanakova, Lada - Moulis, Mojmír - Čech, Zbyněk - Zavřelová, Jiřina - Penka, Miroslav
PY - 2011
TI - Clinical Relevance of uPA, uPAR, PAI 1 and PAI 2 Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patients
JF - Hepatogastroenterology
VL - 58
IS - 112
SP - 1918-1925
EP - 1918-1925
SN - 01726390
KW - Colorectal cancer
KW - Plasminogen activator system
KW - PAI 1
KW - PAI 2
KW - uPA
KW - uPAR
N2 - Urokinase (uPA) is a serine protease, which together with uPAR, tPA, PAI 1 and PAI 2 forms the plasminogen activator system, a component of metastatic cascade contributing to the invasive growth and angiogenesis of malignant tumours. Methodology: Both preceding therapy and after 6-8 weeks of the treatment, plasma PAI 1 levels (photometric microplate method on the ELISA) and uPA, uPAR, PAI 1 and PAI 2 tissue expression (immunohistochemical reaction) were analysed from 80 colorectal carcinoma patients. Results: Analysis showed higher pre-treatment plasma levels of PAI 1 in patients with advanced tumours, which decreased after surgery or the start of therapy (p=0.004); Patients with higher plasma level PAI 1 before (0.013) and after therapy (0.004) had significantly shorter survival. There was a higher expression of uPA (p<0.001), uPAR (p<0.001), PAI 1 (p=0.042) and PAI 2 (p<0.001) in advanced colorectal carcinoma. A relationship between PAI 2 (p=0.010) and uPAR (p=0.019) expression and survival was demonstrated. There is a correlation between pre-treatment plasma PAI 1 levels and PAI 2 (p=0.028) and uPAR (p=0.043) expression. Conclusions: Immunohistochemical analysis of PAS in tumour tissue and plasma PAI 1 levels was found to be a useful prognostic factor in colorectal carcinoma patients. Plasma PAI 1 could be advantageous in evaluating the effectiveness of a mode of treatment.
ER -
HALÁMKOVÁ, Jana, Igor KISS, Zdeněk PAVLOVSKÝ, Jiří JARKOVSKÝ, Jiří TOMÁŠEK, Štěpán TUČEK, Lada HANAKOVA, Mojmír MOULIS, Zbyněk ČECH, Jiřina ZAVŘELOVÁ a Miroslav PENKA. Clinical Relevance of uPA, uPAR, PAI 1 and PAI 2 Tissue Expression and Plasma PAI 1 Level in Colorectal Carcinoma Patients. \textit{Hepatogastroenterology}. 2011, roč.~58, č.~112, s.~1918-1925. ISSN~0172-6390. Dostupné z: https://dx.doi.org/10.5754/hge10232.
|
